IOPtima Overview
IOPtima is a rapidly growing company focused on developing minimally invasive and innovative surgical ophthalmic devices. Its flagship product, the IOPtimate, is a surgical system for the treatment of glaucoma that utilizes CO2 laser technology to significantly reduce internal eye pressure without penetrating the eye. The company also offers a line of patented eye drops to treat ocular surface diseases. IOPtima is a Kanghong Pharmaceutical company.
Cumulative Funding Raised Over Time ($)
Latest News
growth-positive
Chengdu Kanghong Pharma Solidifies Ownership of Israeli Medical Device Company
Chengdu Kanghong Pharma Group has acquired a 41% stake in Tel Aviv-based medical technology company IOPtima for $17.2 million, solidifying its ownership. This investment brings Chengdu Kanghong Pharmas stake in IOPtima to 60%, as they had previously acquired a 19% stake in 2017. Chengdu Kanghong Pharma plans to acquire the remaining stake in two additional stages. IOPtima develops minimally invasive devices for eye surgeries, with its flagship product, IOPtimate, being a laser-based surgical system for the treatment of Glaucoma. The company has regulatory approval for marketing the system in several territories.
InvestmentAcquisition
growth-positive
Chengdu Kanghong Pharma buys Israel's IOPtima for $56m
BioLight Israeli Life Sciences Investments Ltd. has completed the sale of its subsidiary, IOPtima, to Chengdu Kanghong Pharmaceutical Group. The acquisition will generate $23-27.3 million in cash flow for BioLight. Chengdu Kanghong will also become a distributor of IOPtimas products in China. BioLights share price increased by over 10% as a result of the deal.
AcquisitionInvestment
growth-positive
IOPtima launches Lipitear phospholipid microemulsion
IOPtima has launched Lipitear, a phospholipid-based microemulsion that helps restore the ocular surface and enhances corneal re-epithelization after surgery. It reduces symptoms of ocular surface disorder and prevents tear evaporation. The device is currently marketed in Europe under a CE mark but is not yet registered in the United States.
Customers
growth-positive
IOPtima launches iLid CO2 laser kit for blepharoplasty
IOPtima has launched the iLid CO2 laser kit, designed for oculoplastic surgeons to perform CO2 laser-assisted blepharoplasty. The kit offers several benefits, including reduced bruising, swelling, and pain, shorter recovery period, and better cosmetic results. It is based on the IOPtiMate system used for CO2 laser-assisted sclerotomy surgery for glaucoma.
Customers
growth-positive
BioLight to sell IOPtima to Chinese co
BioLight Israeli Life Sciences Investments Ltd. has signed a memorandum of understanding for the sale of its leading product, the only one directly generating revenue for the company, to a Chinese company, Chengdu Kanghong Pharma. Chengdu Kanghong Pharma will invest $7 million in IOPtima for 19% of that companys shares at a $30 million company value. The Chinese company will receive an exclusive license to market IOPtimas product in China. After six months, the Chinese company will acquire additional shares in IOPtima from the existing shareholders, including BioLight, thereby increasing Chengdu Kanghong Pharmas IOPtima stake to 60%, for $17.2 million, reflected a $42 million company value.
AcquisitionInvestment
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $7.2M |
| Last funding | $7.2M |
| Stage | Acquired |
| Rounds | 1 |
| Investors | 3 |
Team Members
3
Employees: 1-10
Web & Social Links
| Website | www.ioptima.com |
Locations
Leshem St 10, Caesarea, Israel
Photos & Videos
2 item(s)
